Compare Novavax Inc (NVAX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Snap On Incorporated — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Snap On Incorporated trades at $377.53 (market cap $19.65B). The key difference: Snap On Incorporated is far larger — about 11.7× Novavax Inc's market cap, and Snap On Incorporated pays a 2.57% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SNA | |
|---|---|---|
Market Cap | $1.68B | $19.65B |
Sector | Health | Technology |
52-Week High | $11.19 | $419.31 |
52-Week Low | $6.22 | $324.16 |
Enterprise Value | $1.26B | $19.28B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% with bearish technical signals but strong fundamentals. The stock shows solid profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $473 price target representing 24.5% upside potential.
SNA presents a compelling value opportunity with premium valuation metrics balanced by robust cash flow generation and dividend stability. Key risks include integration challenges from recent acquisitions and potential margin pressure from rising costs. The stock's current technical weakness may offer entry points for long-term investors seeking quality industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
